The Retain Your Brain Health Study (RetainYourBrain.Com)
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT06027320 |
Recruitment Status :
Active, not recruiting
First Posted : September 7, 2023
Last Update Posted : March 26, 2024
|
Tracking Information | |||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
First Submitted Date ICMJE | August 25, 2023 | ||||||||||||||
First Posted Date ICMJE | September 7, 2023 | ||||||||||||||
Last Update Posted Date | March 26, 2024 | ||||||||||||||
Actual Study Start Date ICMJE | December 7, 2023 | ||||||||||||||
Estimated Primary Completion Date | September 7, 2024 (Final data collection date for primary outcome measure) | ||||||||||||||
Current Primary Outcome Measures ICMJE |
Australian National University Alzheimer's Disease Risk Index (ANU-ADRI) [ Time Frame: Baseline, 3 months and 6 months. ] The ANU-ADRI is an evidence-based, validated tool aimed at assessing individual exposure to risk factors known to be associated with an increased risk of developing late-life Alzheimer's Disease (AD). The ANU-ADRI provides an individualized assessment and has been used in studies aiming to evaluate methods of reducing AD risk.
|
||||||||||||||
Original Primary Outcome Measures ICMJE |
Australian National University-AD Risk Index (ANU-ADRI) [ Time Frame: Baseline, 3 and 6 month. ] The ANU-ADRI is an evidence-based, validated, tool aimed at assessing individual exposure to risk factors known to be associated with an increased risk of developing late-life Alzheimer's Disease (AD). The ANU-ADRI provides an individualized assessment and has been used in studies aiming to evaluate methods of reducing AD risk.
|
||||||||||||||
Change History | |||||||||||||||
Current Secondary Outcome Measures ICMJE |
|
||||||||||||||
Original Secondary Outcome Measures ICMJE |
|
||||||||||||||
Current Other Pre-specified Outcome Measures |
|
||||||||||||||
Original Other Pre-specified Outcome Measures |
|
||||||||||||||
Descriptive Information | |||||||||||||||
Brief Title ICMJE | The Retain Your Brain Health Study (RetainYourBrain.Com) | ||||||||||||||
Official Title ICMJE | Risk Education Technology As Individualized Neuroprotection | ||||||||||||||
Brief Summary | The goal of this clinical trial is to test a cell phone-based online program that provides Alzheimer's risk assessments and memory tests over a 6-month period. The main question it aims to answer is whether online software can help reduce the risk of Alzheimer's disease (AD) through digital education and tracking. Participants will visit RetainYourBrain.com to answer questions about their risk factors for AD and take online word recall and card game cognitive tests. Researchers will track progress over time and compare different strategies of Alzheimer's education to see if it is possible to protect brain health, reduce Alzheimer's risk, and improve memory function. |
||||||||||||||
Detailed Description | Alzheimer's disease (AD) is a public health crisis with few effective treatments. Most people are unaware that AD begins in the brain decades before the first symptoms of memory loss begin. That leaves a lot of time for people to learn their individual risk factors for AD and cognitive decline and take memory assessment screening tests in an effort toward the prevention or delay of dementia. To reach a growing at-risk population, mobile health technologies accessible via cell phone can fill an unmet need due to their accessibility and cost-effective delivery of care. Online education and text messaging have proven to be effective methods of reducing risk for a variety of chronic conditions, including cardiovascular disease and diabetes, which are both key drivers of AD risk. The investigators created a cell phone-based online software application to provide automated, individualized monitoring and education at broad scale. The goal of the software is to function as a digital therapeutic to identify individual risk factors, assess memory and cognitive function over time, and provide education to people with a family history of AD. The system maintains bi-directional communication via text message to verify participant engagement. Potential participants who visit our study website (www.RetainYourBrain.com) will be directed to answer questions assessing eligibility criteria. Participants who are eligible are asked to electronically sign an informed consent form, complete baseline assessments, and take online word recall and card game cognitive tests. Participants will then be randomized to one of two groups using different strategies for AD risk assessment education. Researchers will track progress over six months and compare different strategies of education to determine if it is possible to protect brain health, reduce Alzheimer's risk, and improve memory function. |
||||||||||||||
Study Type ICMJE | Interventional | ||||||||||||||
Study Phase ICMJE | Not Applicable | ||||||||||||||
Study Design ICMJE | Allocation: Randomized Intervention Model: Parallel Assignment Masking: Double (Participant, Outcomes Assessor) Primary Purpose: Prevention |
||||||||||||||
Condition ICMJE |
|
||||||||||||||
Intervention ICMJE |
|
||||||||||||||
Study Arms ICMJE |
|
||||||||||||||
Publications * | Not Provided | ||||||||||||||
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline. |
|||||||||||||||
Recruitment Information | |||||||||||||||
Recruitment Status ICMJE | Active, not recruiting | ||||||||||||||
Estimated Enrollment ICMJE |
736 | ||||||||||||||
Original Estimated Enrollment ICMJE | Same as current | ||||||||||||||
Estimated Study Completion Date ICMJE | September 7, 2024 | ||||||||||||||
Estimated Primary Completion Date | September 7, 2024 (Final data collection date for primary outcome measure) | ||||||||||||||
Eligibility Criteria ICMJE | Inclusion Criteria:
Exclusion Criteria:
|
||||||||||||||
Sex/Gender ICMJE |
|
||||||||||||||
Ages ICMJE | 53 Years to 105 Years (Adult, Older Adult) | ||||||||||||||
Accepts Healthy Volunteers ICMJE | Yes | ||||||||||||||
Contacts ICMJE | Contact information is only displayed when the study is recruiting subjects | ||||||||||||||
Listed Location Countries ICMJE | United States | ||||||||||||||
Removed Location Countries | |||||||||||||||
Administrative Information | |||||||||||||||
NCT Number ICMJE | NCT06027320 | ||||||||||||||
Other Study ID Numbers ICMJE | 20216157 4R44AG071416 ( U.S. NIH Grant/Contract ) |
||||||||||||||
Has Data Monitoring Committee | Yes | ||||||||||||||
U.S. FDA-regulated Product |
|
||||||||||||||
IPD Sharing Statement ICMJE |
|
||||||||||||||
Current Responsible Party | Retain Health, Inc | ||||||||||||||
Original Responsible Party | Same as current | ||||||||||||||
Current Study Sponsor ICMJE | Retain Health, Inc | ||||||||||||||
Original Study Sponsor ICMJE | Same as current | ||||||||||||||
Collaborators ICMJE |
|
||||||||||||||
Investigators ICMJE |
|
||||||||||||||
PRS Account | Retain Health, Inc | ||||||||||||||
Verification Date | December 2023 | ||||||||||||||
ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP |